GS 0976

Drug Profile

GS 0976

Alternative Names: GS-0976; NDI 010976

Latest Information Update: 27 Jul 2017

Price : $50

At a glance

  • Originator Nimbus Therapeutics
  • Developer Gilead Sciences; Nimbus Therapeutics
  • Class Small molecules
  • Mechanism of Action Acetyl-CoA carboxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis

Most Recent Events

  • 21 Apr 2017 Adverse events and pharmacodynamics data from phase II trial in Non-alcoholic steatohepatitis presented at the The International Liver Congress™ 2017 of the European Association for the Study of the Liver (EASL-2017)
  • 19 Apr 2017 Phase-I clinical trials in Non-alcoholic steatohepatitis (In volunteers, Combination therapy) in USA (PO) before April 2017
  • 19 Apr 2017 Pharmacokinetics and adverse events data from a phase I trial in Non-alcoholic steatohepatitis presented at The International Liver Congress 2017 (ILC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top